公开(公告)号：US08563507B2

公开(公告)日：2013-10-22

申请号：US12837992

申请日：2010-07-16

Applicant: Zee Upton ,  Jennifer Ann Kricker

Inventor： Zee Upton ,  Jennifer Ann Kricker

IPC: A61K38/30 ,  C07K14/65 ,  A61P35/00

CPC classification number: A61K47/48246 ,  A61K38/1709 ,  A61K38/30 ,  A61K38/39 ,  C07K14/71 ,  C07K14/78 ,  A61K2300/00

Abstract: An isolated protein complex is provided which includes a growth factor, growth factor binding protein and vitronectin. Preferably, the isolated protein complex includes an insulin-like growth factor-I, insulin-like growth factor binding protein-3 or insulin-like growth factor binding protein-5 and vitronectin. Also provided are methods of modulating cell proliferation and/or migration by administering said protein complex for the purposes of wound healing, skin repair and tissue replacement therapy. Conversely, by using agents that disrupt growth factor protein complexes formed in vivo, growth factor-driven cell proliferation and/or migration may be suppressed such as for the purposes of treating cancers, psoriasis, atherosclerosis and wounds prone to hypertrophic scarring.

Abstract translation: 提供了分离的蛋白质复合物，其包括生长因子，生长因子结合蛋白和玻连蛋白。 优选地，分离的蛋白质复合物包括胰岛素样生长因子-I，胰岛素样生长因子结合蛋白-3或胰岛素样生长因子结合蛋白-5和玻连蛋白。 还提供了通过对于伤口愈合，皮肤修复和组织置换治疗的目的施用所述蛋白质复合物来调节细胞增殖和/或迁移的方法。 相反，通过使用破坏体内形成的生长因子蛋白复合物的试剂，可以抑制生长因子驱动的细胞增殖和/或迁移，例如用于治疗癌症，牛皮癣，动脉粥样硬化和容易发生肥大性瘢痕形成的伤口。

公开(公告)号：US07863430B2

公开(公告)日：2011-01-04

申请号：US10168653

申请日：2001-03-28

Applicant: James Langham Dale ,  Benjamin Dugdale ,  Greg John Hafner ,  Scott Richard Hermann ,  Douglas Kenneth Becker ,  Robert Maxwell Harding ,  Srimek Chowpongpang

Inventor： James Langham Dale ,  Benjamin Dugdale ,  Greg John Hafner ,  Scott Richard Hermann ,  Douglas Kenneth Becker ,  Robert Maxwell Harding ,  Srimek Chowpongpang

IPC: C07H21/04 ,  C12N5/04 ,  A01H1/00

CPC classification number: C12N15/8282 ,  C12N15/79 ,  C12N15/8203 ,  C12N15/8216 ,  C12N15/8257 ,  C12N15/8263 ,  C12N15/8283

Abstract: The present invention relates generally to constructs and in particular genetic constructs comprising polynucleotide sequences capable of release in covalently closed, circular form from a larger nucleotide sequence such as a genome of a eukaryotic cell. Preferably, once released, a polynucleotide sequence is reconstituted in a form which permits expression of the polynucleotide sequence. In one embodiment, the reconstituted polynucleotide sequence comprises a coding sequence with all or part of an extraneous nucleotide such as an intronic sequence or other splice signal inserted therein. Expression and in particular transcription of the coding sequence involves splicing out the extraneous sequence. The release and circularization is generally in response to a stimulus such as a protein-mediated stimulus. More particularly, the protein is a viral or prokaryotic or eukaryotic derived protein or developmentally and/or tissue specific regulated protein.

Abstract translation: 本发明一般涉及构建体，特别是涉及能够从较大核苷酸序列例如真核细胞的基因组以共价闭合的环形形式释放的多核苷酸序列的遗传构建体。 优选地，一旦释放，以允许多核苷酸序列表达的形式重构多核苷酸序列。 在一个实施方案中，重构的多核苷酸序列包含具有全部或部分外来核苷酸（例如插入其中的内含子序列或其它剪接信号）的编码序列。 表达，特别是编码序列的转录涉及剪接外来序列。 释放和环化通常响应于诸如蛋白质介导的刺激的刺激。 更具体地，蛋白质是病毒或原核或真核衍生的蛋白质或发育和/或组织特异性调节蛋白。

公开(公告)号：US07853412B2

公开(公告)日：2010-12-14

申请号：US11916636

申请日：2006-06-08

Applicant: Fujie Xia ,  Peter Joseph Wolfs

Inventor： Fujie Xia ,  Peter Joseph Wolfs

IPC: G01L3/00 ,  G01P15/00

CPC classification number: B61K9/08

Abstract: A method of estimating contact forces between the wheels of a railway wagon and a rail track, for use in determining information such as the likelihood of derailment. Accelerations of the body of the wagon are measured using motion sensors located at suitable points on the body. Forces on the side frames of the wagon are calculated based on the accelerations of the body and predetermined parameters of the body. Forces on the wheels of the wagon are calculated based on the accelerations of the body and predetermined parameters of the body. The contact forces between the wheels and the rails are then calculated based on the forces calculated for the side frames and the wheels. The calculations are carried out using an inverse model of the wagon system. Equipment which implements the method is also described.

Abstract translation: 一种估计铁路车辆的车轮与轨道轨道之间的接触力的方法，用于确定诸如脱轨的可能性之类的信息。 使用位于身体适当位置的运动传感器测量货车车身的加速度。 基于身体的加速度和身体的预定参数计算货车侧框上的力。 根据身体的加速度和身体的预定参数计算货车车轮上的力。 然后基于为侧框架和车轮计算的力计算车轮和轨道之间的接触力。 使用货车系统的逆模型进行计算。 还描述了实现该方法的设备。

公开(公告)号：US20090291432A1

公开(公告)日：2009-11-26

申请号：US11628397

申请日：2005-06-01

Applicant: Charles Phillip Morris ,  Angela Van Daal ,  Christopher Dean Swagell ,  Bruce Robert Lawford ,  Ross McDonald Young

Inventor： Charles Phillip Morris ,  Angela Van Daal ,  Christopher Dean Swagell ,  Bruce Robert Lawford ,  Ross McDonald Young

IPC: C12Q1/68 ,  C07H21/04

CPC classification number: C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/172 ,  G01N2800/28 ,  G01N2800/30

Abstract: The present invention relates to a method for profiling an individual or group of individuals with respect to a neurological, psychiatric or psychological condition, phenotype or state, including a sub-threshold neurological, psychiatric or psychological condition, phenotype or state. More particularly, the present invention identifies a genetic profile associated with the 957C>T polymorphysm within the dopamine receptor D2 (DRD2), indicating a predisposition to schizophrenia and other neurological diseases.

Abstract translation: 本发明涉及一种关于神经，精神或心理状况，表型或状态（包括亚阈值神经，精神或心理状况，表型或状态）的个体或个体个体的分析方法。 更具体地，本发明鉴定与多巴胺受体D2（DRD2）内的957C> T多态性相关的遗传谱，表明精神分裂症和其他神经疾病的倾向。

公开(公告)号：US07598366B2

公开(公告)日：2009-10-06

申请号：US10521571

申请日：2003-07-17

Applicant: James Langham Dale ,  Robert Maxwell Harding ,  Douglas Kenneth Becker ,  Gregory John Hafner ,  Ilin Yang

Inventor： James Langham Dale ,  Robert Maxwell Harding ,  Douglas Kenneth Becker ,  Gregory John Hafner ,  Ilin Yang

IPC: C12N15/82 ,  C12N5/04 ,  C07H21/04 ,  A01H5/00

CPC classification number: C12N15/8216 ,  C07K14/005 ,  C12N15/8222 ,  C12N15/8223 ,  C12N2730/00022

Abstract: This invention discloses a constitutive promoter from the Taro bacilliform virus (TaBV) for expression of foreign or endogenous coding sequences in plants, including dicotyledonous and monocotyledonous plants. The invention also discloses a chimeric nucleic acid construct comprising the promoter of the invention operably linked to a foreign or endogenous polynucleotide that codes for a protein of interest or a transcript capable of modulating expression of a target gene. The invention further discloses transformed plant cells, as well as differentiated plants and plant parts, containing the construct. Methods for diagnosis and treatment of viral infections, especially badnaviral infections, are also disclosed.

Abstract translation: 本发明公开了一种用于在植物中表达外源或内源编码序列的Taro杆菌病毒（TaBV）的组成型启动子，包括双子叶植物和单子叶植物。 本发明还公开了一种嵌合核酸构建体，其包含可操作地连接到编码目标蛋白质的外源或内源多核苷酸的本发明启动子或能够调节靶基因表达的转录物。 本发明还公开了转化的植物细胞，以及含有该构建体的分化植物和植物部分。 还公开了用于诊断和治疗病毒感染，特别是恶毒病毒感染的方法。

公开(公告)号：US20090075827A1

公开(公告)日：2009-03-19

申请号：US12016438

申请日：2008-01-18

Applicant: Ross Young ,  Bruce Lawford ,  C. Phillip Morris ,  Joanne Voisey ,  Ian Hughes ,  Christopher Dean Swagell

Inventor： Ross Young ,  Bruce Lawford ,  C. Phillip Morris ,  Joanne Voisey ,  Ian Hughes ,  Christopher Dean Swagell

IPC: C40B30/00 ,  C40B40/06 ,  C12Q1/68 ,  C12Q1/02 ,  G01N33/566

CPC classification number: C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/172

Abstract: The present invention relates generally to a method and agents for profiling or stratifying an individual or group of individuals with respect to a neurological, psychiatric or psychological condition, phenotype or state, including a sub-threshold neurological, psychiatric or psychological condition, phenotype or state. More particularly, the present invention utilizes genetic means to profile or stratify individuals with respect to a neurological, psychiatric or psychological condition, phenotype or state. The present invention enables the identification of individuals at risk of these disorders thus affording the opportunity for early intervention. In addition, the subject invention allows the prediction of drug or other treatment response and adverse reactions.

Abstract translation: 本发明一般涉及关于神经，精神或心理状况，表型或状态，包括亚阈值神经，精神或心理状况，表型或状态的个体或个体个体的分类或分层的方法和试剂 。 更具体地说，本发明利用遗传方法对个体进行轮廓或分层，这些个体对于神经，精神或心理状况，表型或状态。 本发明能够识别处于这些疾病风险中的个体，从而提供早期干预的机会。 此外，本发明允许预测药物或其他治疗反应和不良反应。

公开(公告)号：US20080299067A1

公开(公告)日：2008-12-04

申请号：US11579378

申请日：2005-05-04

Applicant: Washington Sanchez ,  Graeme Allan George

Inventor： Washington Sanchez ,  Graeme Allan George

IPC: A61K31/765 ,  A61L27/60 ,  A61P17/02

CPC classification number: A61K31/80 ,  A61L26/0019 ,  C08G77/46 ,  C08L83/04

Abstract: A novel composition for use in treating a wound, burn or other skin condition comprises one or more compounds of formula (I), wherein: m = 0-6, n = 6-100, Q, R and R′ may be independently selected from, C1-5 alkyl, OU, UOCH2CH3, CH2CH3, UOCH3, OH, O(CH2)y(OU)yCH3, (OCH2CH2)yOU, (OCH2CH2)yOH, UOH, UOU′, UCO2U′, CO2U, UCO2COU, CO2H, UCO2H, COX, UCOX, UCO2 R′, CO2COU, Aryl, ArylU, ArylUU, ArylUU′U″, NH2, UNH2, NHU, NUU′, NO2, UNO2, UCONH2, CONH2, UCONHU′, CONHU, UCONU′U″, CONU′U″, halogen, PO4H3, PO4H3-z, PO4H3-zU (z = 0, 1, 2 or 3), PU3, P U′U″U′″SH, SO2 and SO3H; wherein U, U′, U″ and U′″ may be independently selected from any alkyl, alkenyl or alkynyl group where the number of carbon atoms is between 1 and 31; wherein X=halogen; wherein y=1-100; provided that Q, R and R′ can not all be C1 alkyl; and wherein the compound of formula (I) is present in an amount of at least 1% of the composition.

Abstract translation: 用于治疗伤口，烧伤或其它皮肤病症的新型组合物包含一种或多种式（I）化合物，其中：m = 0-6，n = 6-100，Q，R和R'可以独立地选择 （OCH 2 CH 2）y OH，（OCH 2 CH 2）y OH，U OH，UOU'，UCO 2 U'，CO 2 U，UCO 2 COU，CO 2 H ，UCO2H，COX，UCOX，UCO2R'，CO2COU，Aryl，ArylU，ArylUU，ArylUU'U“，NH2，UNH2，NHU，NUU'，NO2，UNO2，UCONH2，CONH2，UCONHU'，CONHU，UCONU'U '，CONU'U“，卤素，PO4H3，PO4H3-z，PO4H3-zU（z = 0,1,2或3），PU3，P U'U'U”SH，SO2和SO3H; 其中U，U'，U“和U”可以独立地选自碳原子数在1和31之间的任何烷基，烯基或炔基; 其中X =卤素; 其中y = 1-100; 条件是Q，R和R'不能全部为C1烷基; 并且其中式（I）化合物的存在量为组合物的至少1％。

公开(公告)号：US07289254B2

公开(公告)日：2007-10-30

申请号：US10967593

申请日：2004-10-18

Applicant: Kodikullam V Avudainayagam ,  Chitralekha S Avudainayagam

Inventor： Kodikullam V Avudainayagam ,  Chitralekha S Avudainayagam

IPC: G02B5/32

CPC classification number: A61B3/028 ,  A61B3/0285 ,  A61B3/032 ,  A61B3/08 ,  G02B5/32 ,  G03H1/0005 ,  G03H1/041 ,  G03H1/2249 ,  G03H2001/0033 ,  G03H2001/0413 ,  G03H2001/0428 ,  G03H2210/30

Abstract: The present invention features a method and device for measuring characteristics of the human eye, particularly spherical refractive error. The device comprises a recorded hologram of an array of elements each bearing an identifying indicia. When the reconstructed hologram is viewed by a subject each of the indicia appear at different virtual distances. By indicating which indicia appear to be in focus the spherical refractive error of the eye and the range of accommodation is determined. The indicia are conveniently numbers that indicate dioptres. Also described is an apparatus for working the method. The apparatus can also be used to determine cylinder power and axis, binocular refraction and stereopsis.

Abstract translation: 本发明的特征在于一种用于测量人眼特征的方法和装置，特别是球面屈光不正。 该装置包括每个具有识别标记的元件阵列的记录全息图。 当重建的全息图被对象观看时，每个标记出现在不同的虚拟距离处。 通过指示哪个标记看起来是聚焦的，确定眼睛的球面屈光不正和适应范围。 标记是方便的数字，表示屈光度。 还描述了一种用于工作该方法的装置。 该装置还可用于确定气缸功率和轴，双目折射和立体视觉。

公开(公告)号：US20070243226A1

公开(公告)日：2007-10-18

申请号：US11807476

申请日：2007-05-29

Applicant: Zee Upton ,  Jennifer Kricker

Inventor： Zee Upton ,  Jennifer Kricker

IPC: C07K14/475 ,  A61F2/00 ,  A61K38/18

CPC classification number: A61K47/48246 ,  A61K38/1709 ,  A61K38/30 ,  A61K38/39 ,  C07K14/71 ,  C07K14/78 ,  A61K2300/00

Abstract: An isolated protein complex is provided which includes a growth factor, growth factor binding protein and vitronectin. Preferably, the isolated protein complex includes an insulin-like growth factor-I, insulin-like growth factor binding protein-3 or insulin-like growth factor binding protein-5 and vitronectin. Also provided are methods of modulating cell proliferation and/or migration by administering said protein complex for the purposes of wound healing, skin repair and tissue replacement therapy. Conversely, by using agents that disrupt growth factor protein complexes formed in vivo, growth factor-driven cell proliferation and/or migration may be suppressed such as for the purposes of treating cancers, psoriasis, atherosclerosis and wounds prone to hypertrophic scarring.

Abstract translation: 提供了分离的蛋白质复合物，其包括生长因子，生长因子结合蛋白和玻连蛋白。 优选地，分离的蛋白质复合物包括胰岛素样生长因子-I，胰岛素样生长因子结合蛋白-3或胰岛素样生长因子结合蛋白-5和玻连蛋白。 还提供了通过对于伤口愈合，皮肤修复和组织置换治疗的目的施用所述蛋白质复合物来调节细胞增殖和/或迁移的方法。 相反，通过使用破坏体内形成的生长因子蛋白复合物的试剂，可以抑制生长因子驱动的细胞增殖和/或迁移，例如用于治疗癌症，牛皮癣，动脉粥样硬化和容易发生肥大性瘢痕形成的伤口。

公开(公告)号：US6045578A

公开(公告)日：2000-04-04

申请号：US849196

申请日：1997-09-24

Applicant: Michael John Collins ,  Christine Frances Wildsoet

Inventor： Michael John Collins ,  Christine Frances Wildsoet

IPC: A61F9/00 ,  A61F9/007 ,  A61F2/16

CPC classification number: G02C7/04 ,  A61F9/00 ,  A61F9/007 ,  G02C2202/24

Abstract: Paraxial rays and marginal rays entering the eye do not share a common point of focus in emmetropes, adults usually having a slightly positive spherical aberration. There is provided a method of treatment and prevention of myopia by inducing positive spherical aberration in the myopic eye. The cornea 30 of a myopic eye 31 is fitted with a lens 32 having its outer surface 34 formed having increasing dioptric power away from the axis 35 of the lens and cornea 30. Paraxial light rays 36 entering the central portion 37 of the lens 32 are focused on the retina 40 of the eye 31, producing a clear image of an object. Marginal light rays 41 entering the peripheral portion 42 of the cornea 30 are focused in a plane between the cornea 30 and the retina 40, and produce positive spherical aberration of the image on the latter. This positive spherical aberration produces a physiological effect on the eye which tends to inhibit growth of the eye, thus mitigating the tendency for the myopic eye to grow longer. Methods of treatment of hyperopia, and methods for prevention of focusing disorders based on the same principles are also provided.

Abstract translation: PCT No.PCT / AU95 / 00794 Sec。 371日期：1997年9月29日 102（e）日期1997年9月29日PCT提交1995年11月28日PCT公布。 公开号WO96 / 16621 日期1996年6月6日进入眼睛的射线和边缘射线在正数中不共享一个共同的焦点，成年人通常具有略微正的球面像差。 通过在近视眼中引起正球面像差，提供了治疗和预防近视的方法。 近视眼31的角膜30装配有透镜32，透镜32的外表面34形成为具有较高的屈光度，远离透镜的轴线35和角膜30.进入透镜32的中心部分37的近轴光线36 集中在眼睛31的视网膜40上，产生物体的清晰图像。 进入角膜30的周边部分42的边缘光线41聚焦在角膜30和视网膜40之间的平面中，并产生后者上的图像的正球面像差。 这种正球面像差产生对眼睛的生理作用，其倾向于抑制眼睛的生长，从而减轻近视眼长出的趋势。 还提供了治疗远视的方法以及基于相同原理的预防聚焦障碍的方法。